IM Cannabis Valuation Multiples

Discover IM Cannabis' revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Dogecoin Cash, Sunniva, Green PolkaDot Box, Neon Bloom and more.

IM Cannabis Overview

About IM Cannabis

IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.


Founded

1980

HQ

Israel

Employees

55

Financials (FY)

Revenue: $39M
EBITDA: ($5M)

EV

$11M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

IM Cannabis Financials

IM Cannabis reported last fiscal year revenue of $39M and negative EBITDA of ($5M).

In the same fiscal year, IM Cannabis generated $7M in gross profit, ($5M) in EBITDA losses, and had net loss of ($8M).


IM Cannabis P&L

In the most recent fiscal year, IM Cannabis reported revenue of $39M and EBITDA of ($5M).

IM Cannabis is unprofitable as of last fiscal year, with gross margin of 18%, EBITDA margin of (13%), and net margin of (21%).

See analyst estimates for IM Cannabis
Last FY202320242025202620272028
Revenue$39M$35M$39M$39M
Gross Profit$7M$7M$6M$7M
Gross Margin18%20%16%18%
EBITDA($5M)($2M)($4M)($5M)
EBITDA Margin(13%)(6%)(11%)(13%)
EBIT Margin(21%)(25%)(19%)(21%)
Net Profit($8M)($7M)($8M)($8M)
Net Margin(21%)(19%)(20%)(21%)
Net Debt$9M---

Financial data powered by Morningstar, Inc.

IM Cannabis Stock Performance

IM Cannabis has current market cap of $1M, and enterprise value of $11M.


IM Cannabis' stock price is $0.13.

IM Cannabis has an EPS (earnings per share) of $-0.90.

See more trading valuation data for IM Cannabis
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$11M$1M0.8%---$-0.90

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

IM Cannabis Valuation Multiples

IM Cannabis trades at 0.3x EV/Revenue multiple, and (2.2x) EV/EBITDA.

See NTM and 2027E valuation multiples for IM Cannabis

IM Cannabis Financial Valuation Multiples

As of August 14, 2026, IM Cannabis has market cap of $1M and EV of $11M.

IM Cannabis has a P/E ratio of (0.1x).

Last FY202320242025202620272028
EV/Revenue0.3x0.3x0.3x0.3x
EV/EBITDA(2.2x)(5.6x)(2.5x)(2.2x)
EV/EBIT(1.3x)(1.3x)(1.5x)(1.3x)
EV/Gross Profit1.6x1.6x1.8x1.6x
P/E(0.1x)(0.2x)(0.2x)(0.1x)
EV/FCF3.3x(1.8x)(12.7x)3.3x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified IM Cannabis Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

IM Cannabis Margins & Growth Rates

In the most recent fiscal year, IM Cannabis reported gross margin of 18%, EBITDA margin of (13%), and net margin of (21%).

See estimated margins and future growth rates for IM Cannabis

IM Cannabis Margins

Last FY20242025202720282029
Gross Margin18%16%18%
EBITDA Margin(13%)(11%)(13%)
EBIT Margin(21%)(19%)(21%)
Net Margin(21%)(20%)(21%)
FCF Margin9%(2%)9%

IM Cannabis Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth11%1%
Gross Profit Growth(14%)15%
EBITDA Growth120%13%
EBIT Growth(16%)13%
Net Profit Growth11%7%
FCF Growth(86%)(481%)

Data powered by FactSet, Inc. and Morningstar, Inc.

IM Cannabis Operational KPIs

IM Cannabis' revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.3M for the same period.

Access forward-looking KPIs for IM Cannabis
Last FY202320242025202620272028
Revenue per Employee$0.7M---
Opex per Employee$0.3M---
S&M Expenses to Revenue2%6%4%2%
G&A Expenses to Revenue21%33%21%21%
Opex to Revenue39%45%35%39%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

IM Cannabis Competitors

IM Cannabis competitors include Dogecoin Cash, Sunniva, Green PolkaDot Box, Neon Bloom, Aion Therapeutic, Pharmadrug, RAMM Pharma, SOL Global Investments, Steep Hill and Panacea Life Sciences.

Most IM Cannabis public comparables operate across Cannabis, CannaTech and ViceTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Dogecoin Cash1.2x-(0.1x)-
Sunniva----
Green PolkaDot Box----
Neon Bloom----
Aion Therapeutic11.4x-(0.7x)-
Pharmadrug--(35.7x)-
RAMM Pharma0.3x-(0.1x)-
SOL Global Investments(0.1x)---

This data is available for Pro users. Sign up to see all IM Cannabis competitors and their valuation data.

Start Free Trial

IM Cannabis VC Funding History

Before going public, IM Cannabis raised $15M in total equity funding, across 1 round.


IM Cannabis Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Aug-19Undisclosed stage-$15M--

Acquisitions by IM Cannabis

IM Cannabis has acquired 4 companies to date.

Last acquisition by IM Cannabis was on March 16th 2026. IM Cannabis acquired Blackaxe Technologies for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by IM Cannabis

Blackaxe Technologies
Oranim Pharm
MYM Nutraceuticals
Trichome Financial
Description
Blackaxe Technologies is a Polish supplier of defense and security technologies including satellite-based intelligence and counter-drone systems through partnerships with global technology leaders.
Oranim Pharm is a Haifa-based pharmacy chain in Israel distributing medical cannabis products including oils, flowers, and edibles prescribed for pain management and other conditions. The firm operates multiple outlets and online services compliant with Israeli health regulations.
MYM Nutraceuticals is a Vancouver-based producer of organic medicinal cannabis oils, capsules, and topicals under Health Canada licenses. Its Quebec facilities span 1.5 million square feet for cultivation and extraction, yielding 20,000 kg annually. Products distribute to licensed retailers in Canada via partnerships with Aurora Cannabis. Established in 2016, MYM focuses on CBD-dominant formulations for wellness markets.
Trichome Financial is a Toronto-based specialty lender providing debt financing, working capital, and growth capital to licensed cannabis producers, processors, and distributors in Canada. The firm addresses credit gaps in the industry value chain, supporting expansions, acquisitions, and operations without U.S. assets or activities.
HQ CountryPolandIsraelCanadaCanada
HQ City
-
Jerusalem
Vancouver
Toronto
Deal Date16 Mar 202630 Mar 20221 Apr 202130 Dec 2020
Valuationundisclosed$9M$87M$16M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all IM Cannabis acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About IM Cannabis

When was IM Cannabis founded?IM Cannabis was founded in 1980.
Where is IM Cannabis headquartered?IM Cannabis is headquartered in Israel.
How many employees does IM Cannabis have?As of today, IM Cannabis has over 55 employees.
Is IM Cannabis publicly listed?Yes, IM Cannabis is a public company listed on Nasdaq.
What is the stock symbol of IM Cannabis?IM Cannabis trades under IMCC ticker.
When did IM Cannabis go public?IM Cannabis went public in 1997.
Who are competitors of IM Cannabis?IM Cannabis main competitors include Dogecoin Cash, Sunniva, Green PolkaDot Box, Neon Bloom, Aion Therapeutic, Pharmadrug, RAMM Pharma, SOL Global Investments, Steep Hill, Panacea Life Sciences.
What is the current market cap of IM Cannabis?IM Cannabis' current market cap is $1M.
What is the current revenue of IM Cannabis?IM Cannabis' last fiscal year revenue is $39M.
What is the current EV/Revenue multiple of IM Cannabis?Current revenue multiple of IM Cannabis is 0.3x.
Is IM Cannabis profitable?No, IM Cannabis is not profitable.
How many companies IM Cannabis has acquired to date?As of August 2026, IM Cannabis has acquired 4 companies.
What was the largest acquisition by IM Cannabis?$87M acquisition of MYM Nutraceuticals on 1st April 2021 was the largest M&A IM Cannabis has done to date.
What companies IM Cannabis acquired?IM Cannabis acquired MYM Nutraceuticals, Trichome Financial, Oranim Pharm, and Blackaxe Technologies.
In how many companies IM Cannabis has invested to date?IM Cannabis hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to IM Cannabis

Lists including IM Cannabis

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial